Blood MMP-3 level-lowering agent comprising IL-6 antagonist as active ingredient

• US 20060292147A1
• Filed: 09/01/2006
• Published: 12/28/2006
• Est. Priority Date: 10/27/2000
• Status: Abandoned Application

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Obata, Ken-ichi, Yoshizaki, Kazuyuki, Nishimoto, Norihiro, Okada, Yasunori
• Application Number:
  US11/514,217
• Publication Number:
  US 20060292147A1
• Time in Patent Office: Days
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/248 IL-6

Abstract

A blood matrix metalloprotease-3 (MMP-3) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims

1-24. -24. (canceled)

25. A method of lowering blood matrix metalloprotease-3 (MMP-3) in a patient in need thereof comprising administering interleukin-6 (IL-6) antagonist.

26. The method according to claim 25, in which the IL-6 antagonist is an antibody against IL-6 receptor.

27. The method according to claim 26, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

28. The method according to claim 27, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

29. The method according to claim 27, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

30. The method according to claim 26, in which the antibody against IL-6 receptor is a recombinant antibody.

31. The method according to claim 28, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

32. The method according to claim 29, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

33. The method according to claim 26, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

34. The method according to claim 33, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

35. A method of inhibiting cartilage degradation in a patient in need thereof comprising administering a therapeutically effective amount of interleukin-6 (IL-6) antagonist as an active ingredient.

36. The method according to claim 35, in which the IL-6 antagonist is an antibody against IL-6 receptor.

38. The method according to claim 36, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

40. The method according to claim 36, in which the antibody against IL-6 receptor is a recombinant antibody.

41. The method according to claim 38, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

37. The method according to claim 37, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

39. The method according to claim 37, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

42. The method according to claim 39, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

43. The method according to any one of claim 37, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

44. The method according to claim 43, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

45. A method for treating osteoarthritis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of interleukin-6 (IL-6) antagonist as an active ingredient.

46. A method of detecting, evaluating and determining:

(1) using MMP-3 level in a test sample as an index, and

(2) the effect of (a) a pharmaceutical agent comprising an IL-6 antagonist as an active ingredient, (b) a cartilage degradation inhibitor comprising an IL-6 antagonist as an active ingredient, or (c) a therapeutic agent for osteoarthritis comprising an IL-6 antagonist as an active ingredient.

47. A reagent for determining MMP-3 levels in a test sample for use in a method of detecting, evaluating and determining the effect of (1) inhibiting cartilage degradation by a pharmaceutical agent comprising an IL-6 antagonist as an active ingredient, or (2) treating osteoarthritis by a pharmaceutical agent comprising an IL-6 antagonist as an active ingredient.

48. The reagent according to claim 47 comprising anti-MMP-3 antibody.